These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 32869281)

  • 1. Changing the Clinical Paradigm of Hydroxyurea Treatment for Sickle Cell Anemia Through Precision Medicine.
    Dong M; McGann PT
    Clin Pharmacol Ther; 2021 Jan; 109(1):73-81. PubMed ID: 32869281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hydroxyurea Optimization through Precision Study (HOPS): study protocol for a randomized, multicenter trial in children with sickle cell anemia.
    Meier ER; Creary SE; Heeney MM; Dong M; Appiah-Kubi AO; Nelson SC; Niss O; Piccone C; Quarmyne MO; Quinn CT; Saving KL; Scott JP; Talati R; Latham TS; Pfeiffer A; Shook LM; Vinks AA; Lane A; McGann PT
    Trials; 2020 Nov; 21(1):983. PubMed ID: 33246482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Robust clinical and laboratory response to hydroxyurea using pharmacokinetically guided dosing for young children with sickle cell anemia.
    McGann PT; Niss O; Dong M; Marahatta A; Howard TA; Mizuno T; Lane A; Kalfa TA; Malik P; Quinn CT; Ware RE; Vinks AA
    Am J Hematol; 2019 Aug; 94(8):871-879. PubMed ID: 31106898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early initiation of hydroxyurea (hydroxycarbamide) using individualised, pharmacokinetics-guided dosing can produce sustained and nearly pancellular expression of fetal haemoglobin in children with sickle cell anaemia.
    Quinn CT; Niss O; Dong M; Pfeiffer A; Korpik J; Reynaud M; Bonar H; Kalfa TA; Smart LR; Malik P; Ware RE; Vinks AA; McGann PT
    Br J Haematol; 2021 Aug; 194(3):617-625. PubMed ID: 34227124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Opportunities for model-based precision dosing in the treatment of sickle cell anemia.
    Dong M; Mizuno T; Vinks AA
    Blood Cells Mol Dis; 2017 Sep; 67():143-147. PubMed ID: 28807656
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea treatment for children with sickle cell anemia.
    Ware RE; Despotovic JM; Mortier NA; Flanagan JM; He J; Smeltzer MP; Kimble AC; Aygun B; Wu S; Howard T; Sparreboom A
    Blood; 2011 Nov; 118(18):4985-91. PubMed ID: 21876119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a pharmacokinetic-guided dose individualization strategy for hydroxyurea treatment in children with sickle cell anaemia.
    Dong M; McGann PT; Mizuno T; Ware RE; Vinks AA
    Br J Clin Pharmacol; 2016 Apr; 81(4):742-52. PubMed ID: 26615061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A clinically meaningful fetal hemoglobin threshold for children with sickle cell anemia during hydroxyurea therapy.
    Estepp JH; Smeltzer MP; Kang G; Li C; Wang WC; Abrams C; Aygun B; Ware RE; Nottage K; Hankins JS
    Am J Hematol; 2017 Dec; 92(12):1333-1339. PubMed ID: 28913922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Whole exome sequencing identifies novel genes for fetal hemoglobin response to hydroxyurea in children with sickle cell anemia.
    Sheehan VA; Crosby JR; Sabo A; Mortier NA; Howard TA; Muzny DM; Dugan-Perez S; Aygun B; Nottage KA; Boerwinkle E; Gibbs RA; Ware RE; Flanagan JM
    PLoS One; 2014; 9(10):e110740. PubMed ID: 25360671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rationale, Development, and Validation of HdxSim, a Clinical Decision Support Tool for Model-Informed Precision Dosing of Hydroxyurea for Children with Sickle Cell Anemia.
    Power-Hays A; Dong M; Punt N; Mizuno T; Smart LR; Vinks AA; Ware RE
    Clin Pharmacol Ther; 2024 Sep; 116(3):670-677. PubMed ID: 38018175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hydroxycarbamide: clinical aspects.
    Ware RE
    C R Biol; 2013 Mar; 336(3):177-82. PubMed ID: 23643402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy.
    Ware RE; Eggleston B; Redding-Lallinger R; Wang WC; Smith-Whitley K; Daeschner C; Gee B; Styles LA; Helms RW; Kinney TR; Ohene-Frempong K
    Blood; 2002 Jan; 99(1):10-4. PubMed ID: 11756146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hydroxyurea therapy for sickle cell anemia.
    McGann PT; Ware RE
    Expert Opin Drug Saf; 2015; 14(11):1749-58. PubMed ID: 26366626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment.
    Steinberg MH; Barton F; Castro O; Pegelow CH; Ballas SK; Kutlar A; Orringer E; Bellevue R; Olivieri N; Eckman J; Varma M; Ramirez G; Adler B; Smith W; Carlos T; Ataga K; DeCastro L; Bigelow C; Saunthararajah Y; Telfer M; Vichinsky E; Claster S; Shurin S; Bridges K; Waclawiw M; Bonds D; Terrin M
    JAMA; 2003 Apr; 289(13):1645-51. PubMed ID: 12672732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hydroyxurea improves cerebral oxygen saturation in children with sickle cell anemia.
    Karkoska K; Quinn CT; Niss O; Pfeiffer A; Dong M; Vinks AA; McGann PT
    Am J Hematol; 2021 May; 96(5):538-544. PubMed ID: 33534136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetics and pharmacodynamics of hydroxyurea in sickle cell anemia patients, a basis for optimizing the dosing regimen.
    Paule I; Sassi H; Habibi A; Pham KP; Bachir D; Galactéros F; Girard P; Hulin A; Tod M
    Orphanet J Rare Dis; 2011 May; 6():30. PubMed ID: 21619673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hydroxyurea Dose Escalation for Sickle Cell Anemia in Sub-Saharan Africa.
    John CC; Opoka RO; Latham TS; Hume HA; Nabaggala C; Kasirye P; Ndugwa CM; Lane A; Ware RE
    N Engl J Med; 2020 Jun; 382(26):2524-2533. PubMed ID: 32579813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hydroxyurea: Analytical techniques and quantitative analysis.
    Marahatta A; Ware RE
    Blood Cells Mol Dis; 2017 Sep; 67():135-142. PubMed ID: 28847416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spectrum of fetal hemoglobin responses in sickle cell patients treated with hydroxyurea: the National Institutes of Health experience.
    Rodgers GP
    Semin Oncol; 1992 Jun; 19(3 Suppl 9):67-73. PubMed ID: 1379375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-Effectiveness of Hydroxyurea for Sickle Cell Anemia in a Low-Income African Setting: A Model-Based Evaluation of Two Dosing Regimens.
    Teigen D; Opoka RO; Kasirye P; Nabaggala C; Hume HA; Blomberg B; John CC; Ware RE; Robberstad B
    Pharmacoeconomics; 2023 Dec; 41(12):1603-1615. PubMed ID: 37462838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.